From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Psychiatry>
  4. Summary and Comment

Thimerosal and Neurotoxicity

The effect of mercury exposure in children once again proves difficult to determine.

Considerable controversy surrounds the question of whether mercury preservatives in vaccines, such as thimerosal, are associated with impaired behaviors or cognition in children (see Journal Watch Psychiatry Aug 4 2004). These researchers examined 42 measures of neuropsychological and behavioral functioning in children aged 7 to 10 years from four HMOs. Using histories of vaccination, immunoglobulin experience, and other records, the researchers retrospectively calculated mercury exposure at three time points: neonatal (i.e., maternal), the first 28 days of life, and the first 7 months.

Children with low birth weight, meningitis, encephalitis, or other serious neurological diagnoses were excluded. The 1047 tested children represented only 30% of those eligible. Children of parents with the highest socioeconomic indicators had the highest exposure. Small yet significant negative and positive associations, some sex-specific, were identified between some individual neuropsychological tests and thimerosal exposure.

Comment: The authors, who expertly analyzed these data statistically, conclude that thimerosal does not produce meaningful clinical problems. However, the validity of this conclusion needs to be questioned because of possible confounding in the study sample. First, only 30% of cases were studied; how these cases may have differed from those who did not participate was not discussed. Second, the data were collected retrospectively. Third, the cases that were excluded — e.g., low-birth-weight babies — might be the ones most vulnerable to the effect of a neuroactive substance, but this issue was not addressed. Finally, the threshold dose for neurological impairment is unknown; therefore, to dismiss the vaccines given between ages 12 months and 7 years may be premature. Parents who ask about this issue still need to be informed of the complexities of studying this problem.

Barbara Geller, MD

Published in Journal Watch Psychiatry September 26, 2007

Citation(s):

Thompson WW et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007 Sep 27; 357:1281.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2007. Massachusetts Medical Society. All rights reserved.